Therapy: Lenvatinib and radioiodine-refractory thyroid cancers

@article{Dunn2015TherapyLA,
  title={Therapy: Lenvatinib and radioiodine-refractory thyroid cancers},
  author={L. Dunn and J. Fagin},
  journal={Nature Reviews Endocrinology},
  year={2015},
  volume={11},
  pages={325-327}
}
Over the past decade, several multikinase inhibitors have shown considerable effectiveness against metastatic radioiodine-refractory thyroid cancers in early stage clinical trials. On the basis of some remarkable results in a phase III clinical trial, lenvatinib now joins sorafenib as another multikinase inhibitor approved by the FDA for this disease. 

References

SHOWING 1-10 OF 14 REFERENCES
A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.
  • E. Sherman, A. Ho, +8 authors D. Pfister
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Thyroid carcinoma, version 2.2014.
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.
  • R. Jain
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
...
1
2
...